8-K: Curis Announces Positive Regulatory Feedback and Fourth Quarter 2024 Financial Results

Curis, Inc. reports successful discussions with the FDA and EMA regarding accelerated approval for emavusertib in PCNSL, along with fourth quarter 2024 financial results and a recent $10 million capital raise.

Summary

• Curis, Inc. announced its fourth quarter and full year 2024 financial results and provided a business update on March 31, 2025.
• The company completed discussions with the FDA and EMA, receiving supportive feedback for a potential accelerated approval path for emavusertib in PCNSL.
• Emavusertib was granted Orphan Drug Designation for PCNSL in both the US and Europe.
• Clinical data from the TakeAim Lymphoma study showed promising results in relapsed/refractory PCNSL patients, with objective responses observed in both BTKi-experienced and BTKi-naive patients.
• Data from the TakeAim Leukemia study in R/R AML showed objective responses in patients with FLT3 mutations treated with emavusertib monotherapy.
• Curis initiated a Phase 1 clinical study of emavusertib in combination with venetoclax and azacitidine in frontline AML.
• The company priced a registered direct offering of common stock and concurrent private placement of pre-funded warrants and warrants in March 2025, expecting gross proceeds of approximately $10.0 million.
• Curis reported a net loss of $43.4 million for the year ended December 31, 2024, and a net loss of $9.6 million for the fourth quarter of 2024.
• Revenues for the year ended December 31, 2024, were $10.9 million, and $3.3 million for the fourth quarter, primarily from Erivedge royalties.
• The company expects its cash and cash equivalents, along with proceeds from the March 2025 Offerings, to fund operations into the fourth quarter of 2025.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. Positive regulatory feedback and promising clinical data are encouraging, but the company's financial losses and need for additional capital raise concerns. The sentiment is cautiously optimistic.

Positives

• Supportive feedback from the FDA and EMA for potential accelerated approval of emavusertib in PCNSL is a major positive step.
• Orphan Drug Designation for emavusertib in PCNSL provides potential benefits such as market exclusivity and tax credits.
• Promising clinical data from the TakeAim Lymphoma and Leukemia studies suggest potential efficacy of emavusertib in treating PCNSL and AML.
• Initiation of a Phase 1 clinical study of emavusertib in combination with venetoclax and azacitidine in frontline AML expands the potential applications of the drug.
• The recent $10 million capital raise strengthens the company's financial position.

Negatives

• Curis reported a net loss of $43.4 million for the year ended December 31, 2024.
• The company's cash and cash equivalents totaled $20.0 million as of December 31, 2024.
• Two patients in the TakeAim Leukemia study were not response-evaluable due to death prior to first disease assessment.

Risks

• The success of emavusertib is critical to Curis's future, and any delays in its development could have a material adverse effect.
• Curis will require substantial additional capital to fund its business and may be forced to delay or reduce the scope of its development programs if it cannot obtain sufficient funding.
• Clinical trial results may not be sufficient for Curis to successfully achieve conditional marketing authorization from the EMA or accelerated approval from the FDA for emavusertib.
• Curis faces substantial competition in the pharmaceutical industry.
• Unstable market and economic conditions could significantly disrupt Curis's operations.

Future Outlook

Curis expects its cash and cash equivalents as of December 31, 2024, together with the expected proceeds from the March 2025 Offerings will enable the Company to fund its planned operations into the fourth quarter of 2025. Over the next 12-18 months, the company will be focused on enrolling 30-40 additional patients to support the regulatory filing for accelerated approval.

Management Comments

• Curis had a very productive 2024.
• We started the year seeing early responses in our PCNSL trial.
• As more patients enrolled, and we continued to see positive data, we initiated discussions with the FDA and EMA to discuss the possibility of pursuing an accelerated approval path for emavusertib.
• We are pleased to announce today that we have received supportive feedback from both agencies.
• Over the next 12-18 months, we will be focused on enrolling 30-40 additional patients to support the regulatory filing for accelerated approval.

Industry Context

Curis is focused on developing emavusertib, an IRAK4 inhibitor, for hematologic malignancies. The positive feedback from regulatory agencies and promising clinical data position Curis favorably in the competitive landscape of cancer therapeutics, particularly in the treatment of PCNSL and AML. The company's approach of combining emavusertib with other therapies like venetoclax and azacitidine reflects a growing trend in oncology to improve treatment outcomes through synergistic drug combinations.

Comparison to Industry Standards

• The objective response rates observed in the TakeAim Lymphoma and Leukemia studies appear competitive with other therapies targeting relapsed/refractory PCNSL and AML.
• For example, in PCNSL, high-dose methotrexate-based regimens are a standard of care, but outcomes in relapsed/refractory settings remain poor, suggesting a need for novel therapies like emavusertib.
• In AML, venetoclax-based combinations have become a standard of care for frontline treatment, and Curis's ema-ven-aza triplet study aims to improve outcomes further by targeting minimal residual disease.
• Companies like AbbVie (venetoclax) and Roche (Erivedge) are key players in the hematology/oncology space, and Curis's success will depend on demonstrating a differentiated clinical profile for emavusertib.

Stakeholder Impact

• Shareholders: The positive regulatory feedback and clinical data could positively impact shareholder value, but the company's financial losses and need for additional capital may raise concerns.
• Employees: Continued progress in the development of emavusertib could provide job security and growth opportunities for employees.
• Patients: Successful development and approval of emavusertib could provide a new treatment option for patients with PCNSL and AML.
• Creditors: The recent capital raise improves the company's ability to meet its financial obligations.

Next Steps

• Enroll 30-40 additional patients in the TakeAim Lymphoma study to support the regulatory filing for accelerated approval.
• Continue the Phase 1 clinical study of emavusertib in combination with venetoclax and azacitidine in frontline AML.
• Pursue regulatory submissions to the EMA and FDA for emavusertib in the treatment of PCNSL.

Key Dates

Keywords

emavusertib, PCNSL, AML, IRAK4 inhibitor, FDA, EMA, TakeAim Lymphoma, TakeAim Leukemia, Orphan Drug Designation, Clinical Trial, Accelerated Approval, Financial Results, Curis